149 related articles for article (PubMed ID: 11158413)
1. Plasma transforming growth factor beta(1) and platelet activation: implications for studies in transplant recipients.
Coupes BM; Williams S; Roberts IS; Short CD; Brenchley PE
Nephrol Dial Transplant; 2001 Feb; 16(2):361-7. PubMed ID: 11158413
[TBL] [Abstract][Full Text] [Related]
2. Plasma levels of transforming growth factor-beta1 in renal transplant recipients receiving different immunosuppressive regimens.
Citterio F; Pozzetto U; Romagnoli J; Tondolo E; Silvestri P; Nanni G; Castagneto M
Transplant Proc; 2004 Apr; 36(3):698-9. PubMed ID: 15110635
[TBL] [Abstract][Full Text] [Related]
3. Plasma TGF-beta1 as a risk factor for gingival overgrowth.
Ellis JS; Morgan CL; Kirby JA; Taylor JJ; Thomason JM
J Clin Periodontol; 2004 Oct; 31(10):863-8. PubMed ID: 15367190
[TBL] [Abstract][Full Text] [Related]
4. Transforming growth factor beta 1 in renal allograft recipients.
Coupes BM; Newstead CG; Short CD; Brenchley PE
Transplantation; 1994 Jun; 57(12):1727-31. PubMed ID: 8016876
[TBL] [Abstract][Full Text] [Related]
5. The relationship of transforming growth factor-beta1 gene polymorphism, its plasma level, and gingival overgrowth in renal transplant recipients receiving different immunosuppressive regimens.
Radwan-Oczko M; Boratyńska M; Zietek M; Zołedziewska M; Jonkisz A
J Periodontol; 2006 May; 77(5):865-73. PubMed ID: 16671880
[TBL] [Abstract][Full Text] [Related]
6. Molecular and structural consequences of early renal allograft injury.
Baboolal K; Jones GA; Janezic A; Griffiths DR; Jurewicz WA
Kidney Int; 2002 Feb; 61(2):686-96. PubMed ID: 11849412
[TBL] [Abstract][Full Text] [Related]
7. Serum TGF-beta1 correlates with chronic histopathological lesions in protocol biopsies of kidney allograft recipients.
Baczkowska T; Perkowska-Ptasińska A; Sadowska A; Lewandowski Z; Nowacka-Cieciura E; Cieciura T; Pazik J; Lewandowska D; Mroz A; Urbanowicz A; Nazarewski S; Danielewicz R
Transplant Proc; 2005 Mar; 37(2):773-5. PubMed ID: 15848527
[TBL] [Abstract][Full Text] [Related]
8. Intragraft messenger RNA expression of angiotensinogen: relationship with transforming growth factor beta-1 and chronic allograft nephropathy in kidney transplant patients.
Mas V; Alvarellos T; Giraudo C; Massari P; De Boccardo G
Transplantation; 2002 Sep; 74(5):718-21. PubMed ID: 12352892
[TBL] [Abstract][Full Text] [Related]
9. Blood levels of TGFbeta1 in liver transplant recipients receiving either tacrolimus or micro-emulsified cyclosporine.
Hughes JR; Hughes VF; Trull AK; Metcalfe SM
Transplantation; 1999 Aug; 68(4):583-6. PubMed ID: 10480422
[TBL] [Abstract][Full Text] [Related]
10. Anti-inflammatory effects of clopidogrel intake in renal transplant patients: effects on platelet-leukocyte interactions, platelet CD40 ligand expression, and proinflammatory biomarkers.
Graff J; Harder S; Wahl O; Scheuermann EH; Gossmann J
Clin Pharmacol Ther; 2005 Nov; 78(5):468-76. PubMed ID: 16321613
[TBL] [Abstract][Full Text] [Related]
11. Urinary transforming growth factor-beta1 excretion in renal allograft recipients during the early post-transplantation period.
Goumenos DS; Tsakas S; Karavias D; Savidaki I; Karatzas T; Vlachojannis JG
Ren Fail; 2003 Jul; 25(4):561-8. PubMed ID: 12911160
[TBL] [Abstract][Full Text] [Related]
12. The effect of leflunomide analogue FK778 on development of chronic rat renal allograft rejection and transforming growth factor-BETA expression.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Transplant Proc; 2006 Dec; 38(10):3239-40. PubMed ID: 17175234
[TBL] [Abstract][Full Text] [Related]
13. Transforming growth factor-beta1 gene expression and cyclosporine A-induced gingival overgrowth: a pilot study.
Radwan-Oczko M; Boratyńska M; Zietek M; Dobosz T
J Clin Periodontol; 2008 May; 35(5):371-8. PubMed ID: 18355347
[TBL] [Abstract][Full Text] [Related]
14. FK778 ameliorates post-transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts.
Rintala JM; Savikko J; Rintala SE; von Willebrand E
Nephrol Dial Transplant; 2008 Nov; 23(11):3446-55. PubMed ID: 18558624
[TBL] [Abstract][Full Text] [Related]
15. Immunosuppressive therapy regimen and platelet activation in renal transplant patients.
Graff J; Klinkhardt U; Harder S; Wegert W; Lenz T; Scheuermann EH; Gossmann J
Clin Pharmacol Ther; 2002 Oct; 72(4):411-8. PubMed ID: 12386643
[TBL] [Abstract][Full Text] [Related]
16. Anti-transforming growth factor antibody at low but not high doses limits cyclosporine-mediated nephrotoxicity without altering rat cardiac allograft survival: potential of therapeutic applications.
Khanna AK; Plummer MS; Hilton G; Pieper GM; Ledbetter S
Circulation; 2004 Dec; 110(25):3822-9. PubMed ID: 15583082
[TBL] [Abstract][Full Text] [Related]
17. Plateletpheresis does not cause long-standing platelet-derived growth factor release into the donor blood.
Zimmermann R; Loew D; Weisbach V; Strasser E; Ringwald J; Zingsem J; Eckstein R
Transfusion; 2005 Mar; 45(3):414-9. PubMed ID: 15752160
[TBL] [Abstract][Full Text] [Related]
18. Circulating TGF-β1 and VEGF and risk of cancer among liver transplant recipients.
Engels EA; Jennings L; Kemp TJ; Chaturvedi AK; Pinto LA; Pfeiffer RM; Trotter JF; Acker M; Onaca N; Klintmalm GB
Cancer Med; 2015 Aug; 4(8):1252-7. PubMed ID: 25919050
[TBL] [Abstract][Full Text] [Related]
19. Active TGF-beta1 expression in kidney transplantation: a comparative study of cyclosporin-A (CyA) and tacrolimus (FK506).
Mohamed MA; Robertson H; Booth TA; Balupuri S; Gerstenkorn C; Kirby JA; Talbot D
Transpl Int; 2000; 13 Suppl 1():S295-8. PubMed ID: 11112017
[TBL] [Abstract][Full Text] [Related]
20. TGF-beta expression in renal transplant biopsies: a comparative study between cyclosporin-A and tacrolimus.
Mohamed MA; Robertson H; Booth TA; Balupuri S; Kirby JA; Talbot D
Transplantation; 2000 Mar; 69(5):1002-5. PubMed ID: 10755567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
